Skip to main content
SpringerLink
Log in

Involvement of Patients in Pharmacovigilance

  • Reference work entry
  • First Online:
Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

  • 179 Accesses

Abstract

Pharmacovigilance is an essential aspect of drug safety that involves the detection, assessment, and prevention of adverse drug reactions. Patients can play a crucial role in pharmacovigilance by providing valuable feedback on their experiences with medication. This chapter will examine the different ways in which patients can be involved in pharmacovigilance, including reporting adverse drug reactions, providing feedback on drug efficacy and safety, and educating other patients. By actively involving patients in pharmacovigilance, we can improve drug safety, enhance patient care, and promote a culture of safety and transparency in the healthcare industry. This chapter will also explore the challenges and opportunities associated with involving patients in pharmacovigilance and offer practical guidance on how to engage patients effectively in this critical process.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 999.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aagaard L, Hansen E. Consumers’ reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69(3):317–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32(11):1067–74.

    Article  PubMed  Google Scholar 

  • Ahmed AM, Izham IM, Subish P. The importance of the consumer pharmacovigilance system in developing countries: a case of Malaysia. J Clin Diagn Res. 2010;4:2929–35.

    Google Scholar 

  • Aronson JK. Artificial intelligence in pharmacovigilance: an introduction to terms, concepts, applications, and limitations. Drug Saf. 2022;45(5):407–18.

    Article  PubMed  Google Scholar 

  • Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC. Evaluation of patient reporting of adverse drug reactions to the UK “Yellow Card Scheme”: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234. iii–iv

    Article  CAS  PubMed  Google Scholar 

  • Banovac M, Candore G, Slattery J, Houyez F, Haerry D, Genov G, Arlett P. Patient reporting in the EU: analysis of EudraVigilance data. Drug Saf. 2017;24(2):152–8.

    Google Scholar 

  • Basch E. Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf. 2013;36(4):277–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77.

    Article  PubMed  Google Scholar 

  • Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.

    Article  CAS  PubMed  Google Scholar 

  • Chebane L, Abadie D, Bagheri H, Durrieu G, Montastruc J. Patient reporting of adverse drug reactions; experience of Toulouse Regional Pharmacovigilance Center. Drug Saf. 2012;35(10):877–970.

    Google Scholar 

  • Clothier H, Selvaraj G, Easton M, Lewis G, Crawford N, Buttery J. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726–30.

    Article  PubMed  PubMed Central  Google Scholar 

  • de Langen J, van Hunsel F, Passier A, de Jongvan den Berg LTW, van Grootheest AC. Adverse drug reaction reporting by patients in the Netherlands, three years of experience. Drug Saf. 2008;31(6):515–24. 34

    Article  PubMed  Google Scholar 

  • Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. Drug Saf. 2012;35(10):845–54.

    Article  PubMed  Google Scholar 

  • European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module IX – Signal management. www.ema.europa.eu/docs/.../WC500129131.pdf. Access date: 31 Mar 2023

  • Fernandopulle RBM, Weerasuriya K. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Saf. 2003;26(4):219–25.

    Article  PubMed  Google Scholar 

  • Harmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, Kant A. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39(10):883–90.

    Article  PubMed  Google Scholar 

  • Jacobs TG, Ampadu HH, Hoekman J, Dodoo ANO, Mantel-Teeuwisse AK. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health. 2018;18:1–18.

    Article  Google Scholar 

  • Jansson K, Ekbom Y, Sjölin-Forsberg G. Basic conditions for consumer reporting of adverse drug reactions in Sweden – a pilot study (abstract 28). Drug Saf. 2006;29(10):938.

    Article  Google Scholar 

  • Jindrich Srba JV. Position and processing of adverse drug reactions directly submitted by patients to national regulatory authorities in Europe. J Pharmacovigilance. 2014;2:122.

    Article  Google Scholar 

  • Jones JK, Andrews EB KE, Moore N, editors. Mann’s pharmacovigilance, History of pharmacovigilance, vol. 2. 3rd ed. Oxford, UK; 2014. p. 11–24.

    Google Scholar 

  • Jones CA, Clark EM, Weintraub A, Zia A. Personalized adaptive rewards versus incentives to motivate sustainable healthy behavioral change-a neo-maslowian conceptual model. Value Health. 2016;19(7):A823–4.

    Article  Google Scholar 

  • Khan MAA, Hamid S, Khan SA, Sarfraz M, ZUD B. A qualitative study of stakeholders’ views on pharmacovigilance system, policy, and coordination in Pakistan. Front Pharmacol. 2022;13:1–13.

    Article  Google Scholar 

  • Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low and middle income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491–509.

    Article  PubMed  Google Scholar 

  • Kim BY, Sharafoddini A, Tran N, Wen EY, Lee J. Consumer mobile apps for potential drug-drug interaction check: systematic review and content analysis using the mobile app rating scale (MARS). JMIR mHealth uHealth. 2018;6(3):e8613.

    Article  Google Scholar 

  • Leal MM, Sanz MM, Ferrando JRC, Martinez-Martinez F. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites. DARU J Pharma Sci. 2019;27:379–87.

    Article  Google Scholar 

  • Leone R, Moretti U, D’Incau P, Conforti A, Magro L, Lora R, Velo G. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first italian study. Drug Saf. 2013;36(4):267–76.

    Article  PubMed  Google Scholar 

  • Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–19.

    Article  CAS  PubMed  Google Scholar 

  • McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010;33(9):775–88.

    Article  PubMed  Google Scholar 

  • Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of depencence and suicidal behaviour with paroxetine. Int J Risk Saf Med. 2003;16:5–19.

    Google Scholar 

  • Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Montastruc JL. Adverse drug reaction reports received through the mobile app, VigiBIP®: a comparison with classical methods of reporting. Drug Saf. 2018;41:511–4.

    Article  PubMed  Google Scholar 

  • Paola K, Claudio G. The value of direct patient reporting in pharmacovigilance. Ther Adv Drug Saf. 2020;11:1–14.

    Article  Google Scholar 

  • Parretta E, Rafaniello C, Magro L, Coggiola PA, Sportiello L, Ferrajolo C, Mascolo A, Sessa MRossi F, Capuano A. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opin Drug Saf. 2014;13(1):21–9.

    Article  Google Scholar 

  • Pharmacovigilance Systems in Five Asian Countries. USAID. SIAP. https://siapsprogram.org/wp-content/uploads/2014/02/Asia-PV-report.pdf. Access date: 31 Mar 2023

  • Sabblah GT, Seaneke SK, Kushitor M, van Hunsel F, Taxis K, Duwiejua M, van Puijenbroek E. Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach. PLoS One. 2022;22:1–12.

    Google Scholar 

  • Saleh HA, Fourrier-Réglat A, Diogène E. Patient-centered pharmacovigilance: a review. Trop J Pharm Res. 2018;17(1):179–88.

    Article  Google Scholar 

  • Uppsala Monitoring Centre. VigiBase. https://www.who-umc.org/vigibase/vigibase/. Accessed: 31 Mar 2023

  • van Grootheest AC, Passier JL, van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year (article in Dutch). Ned Tijdschr Geneeskd. 2005;149(10):529–33.

    PubMed  Google Scholar 

  • van Hunsel F, Härmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients; an 11-country survey. Drug Saf. 2012;35(1):45–60.

    Article  PubMed  Google Scholar 

  • Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association. BMC Clin Pharmacol. 2011;11:16.

    Article  PubMed  PubMed Central  Google Scholar 

  • Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association. BMC Pharmacol Toxicol. 2012;13:19–44.

    Article  PubMed  PubMed Central  Google Scholar 

  • Waller P, Harrison-Woolrych M. An introduction to pharmacovigilance. Wiley; 2017.

    Book  Google Scholar 

  • World Health Organization. The WHO Programme for International Drug Monitoring. (version date: 2017). http://www.who.int/medicines/areas/quality_safety/saf. Access date: 31 Mar 2023

  • Yawson AA, Abekah-Nkrumah G, Okai GA, Ofori CG. Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana. Ther Adv Drug Safe. 2022;13:1–14.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Security Forces Hospital, Riyadh, Saudi Arabia

    Fahad Alshahrani

Authors
  1. Fahad Alshahrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fahad Alshahrani .

Editor information

Editors and Affiliations

  1. Medicines and Healthcare, Department of Pharmacy, University of Huddersfield, Huddersfield, UK

    Zaheer-Ud-Din Babar

Section Editor information

  1. Department of Pharmacy, Centre for Pharmaceutical Policy and Practice Research, University of Huddersfield, Huddersfield, UK

    Zaheer-Ud-Din Babar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Alshahrani, F. (2023). Involvement of Patients in Pharmacovigilance. In: Babar, ZUD. (eds) Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-64477-2_143

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-64477-2_143

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-64476-5

  • Online ISBN: 978-3-030-64477-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation